Filing Flows › Arcadia Biosciences (RKDA) › Q3 2025
Arcadia Biosciences (RKDA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
Arcadia Biosciences (RKDA) reported revenue of $1.3M for the third quarter 2025 (Q3 2025), -15% from a year earlier and -11% from the quarter before. Operating margin was -88.5%, net earnings $856K (65.7% of revenue).
Arcadia Biosciences, Q3 2025: revenue $1.3M (-15% year over year), operating margin -88.5%, net earnings $856K, operating cash flow −$257K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | -11% | -15% |
| Operating profit | −$1.2M | — | — |
| Net earnings | $856K | — | — |
| Operating cash flow | −$257K | — | — |
What changed
Revenue was $1.3M in Q3 2025, down 15% year over year and down 11% from the previous quarter.
Operating costs exceeded revenue by $1.2M, an operating margin of -88.5%. Total costs fell 26% while revenue fell 15%. Net earnings were $856K. The effective tax rate was 0.0%. Non-operating items added $2.0M, 235% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$257K. Non-cash charges added back $2K of depreciation and $53K of share-based compensation. Working capital and other items used $1.2M.
Questions
What was Arcadia Biosciences' revenue in the third quarter 2025?
Arcadia Biosciences (RKDA) reported revenue of $1.3M for the third quarter 2025 (Q3 2025), -15% from a year earlier and -11% from the quarter before.
Was Arcadia Biosciences profitable in the third quarter 2025?
Operating loss was $1.2M (-88.5% of revenue) and net earnings $856K.